Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Australia’s Prana Biotech Phase II Data On Huntington’s Candidate Holds Investor Interest With More To Come

This article was originally published in PharmAsia News

Executive Summary

Australia’s Prana Biotechnology has Phase II clinical trial data on a potential Huntington’s disease therapy to sustain a surge in the share price over the past year with more possibly on the way for an Alzheimer’s therapy.

You may also be interested in...



Sangamo On A Roll, Clarifies Timelines And Catalysts, Takes On CRISPR

Sangamo used 2013 to progress its pipeline, to raise money and to acquire a company. The momentum carried into the first quarter of 2014 with the Biogen partnership and a jump in share price that suggested that investors finally may have bought into the gene therapy company’s unique story.

G8 Agrees World Will Tackle Alzheimer’s, But Solutions Are Some Way Off

The G8 dementia summit saw politicians, health stakeholders and financiers agree to target Alzheimer’s disease together, but a silver bullet may be years away.

Lilly’s Late-Stage CNS Pipeline Bare Following Edivoxetine Failure

Depression candidate edivoxetine fails in three Phase III studies, marking a third recent blow to Lilly’s neuroscience pipeline efforts.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID017698

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel